UNSPSC 51392220: Detomidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H14N2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95K4LKB6QE, chemically known as 4-((2,3-dimethylphenyl)methyl)-1h-imidazole hydrochloride but more generally known as detomidine hydrochloride, which bears US NIH Compound Identifier 56031. European Medicines Agency schedules Detomidine hydrochloride for veterinary use in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11892MIG.

UNSPSC 51392220 Detomidine hydrochloride is a Commodity code that nominally identifies a specific veterinary sedative, but recent state and local activity shows a significant mismatch between the code's stated scope and what is actually being procured. The recent opportunities tagged under this code involve procurement of naloxone (an opioid antagonist used in overdose response) and pharmacy benefit management services — neither of which falls within detomidine hydrochloride's veterinary pharmaceutical scope. The code shows little relevant recent activity for the product it names. Issuing bodies placing opportunities under this code include county health departments and state health and human services commissions, suggesting broader pharmaceutical and pharmacy-services procurement activity, but the opportunities themselves do not reflect detomidine-specific purchasing.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program — an exploratory procurement mechanism seeking information on direct contracting models for prescription fulfillment with self-insured employers and state agencies. Neither opportunity represents procurement of detomidine hydrochloride itself, indicating that the code's application to these opportunities reflects either data-entry misclassification or a broader pharmaceutical taxonomy issue rather than genuine market activity under the stated commodity code.